» Articles » PMID: 21459613

Challenging the Surgical Rodent Hindlimb Ischemia Model with the Miniinterventional Technique

Overview
Date 2011 Apr 5
PMID 21459613
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To develop an interventional hindlimb ischemic model and compare its angiogenic effect versus surgical ligation (SL) and excision of the femoral artery in rats treated with transplantation of bone marrow mononuclear cells (MNCs) as an angiogenic stimulator.

Materials And Methods: Forty-eight Lewis rats randomly received interventional embolization (IE) with hydrogel wire or SL and excision of the right femoral artery. Rodents were intraarterially transplanted with 1.5 × 10(7) MNCs in 500 μL medium from 24 isogenic donor rats. Functional and structural recovery was evaluated by laser Doppler imaging (LDI), cytokine/chemokine assay, and histologic staining.

Results: In vivo microscopic images showed significantly dilated vasa vasorum around the embolized segment of the right femoral artery at 3 days compared with disorganized tissue structure in the SL group. However, the LDI index was significantly higher in the SL group at 3 days compared with the IE group. LDI did not significantly differ between the two groups at 2 weeks after transplantation. Cytokine assay showed higher levels of interleukin (IL)-1α and IL-18 in the SL group; the IE group had higher levels of interferon-γ, IL-6, IL-13, and granulocyte colony-stimulating factor. Histologic examination demonstrated inflammatory infiltration near the incision within nerve fibers with dilated capillaries, showing nerve degeneration in the SL group. At 2 weeks, histologic analysis demonstrated massive scarring under the skin spreading into the musculature in the SL group.

Conclusions: A minimally invasive hindlimb ischemia model has been successfully developed that preserves tissue integrity and minimizes inflammation and confounding factors in the early stages of angiogenesis and arteriogenesis.

Citing Articles

Latrophilin-2 mediates fluid shear stress mechanotransduction at endothelial junctions.

Tanaka K, Chen M, Prendergast A, Zhuang Z, Nasiri A, Joshi D EMBO J. 2024; 43(15):3175-3191.

PMID: 38886581 PMC: 11294477. DOI: 10.1038/s44318-024-00142-0.


Alginate-Encapsulated Mesenchymal Stromal Cells Improve Hind Limb Ischemia in a Translational Swine Model.

Deppen J, Ginn S, Tang E, Wang L, Brockman M, Levit R J Am Heart Assoc. 2024; 13(9):e029880.

PMID: 38639336 PMC: 11179867. DOI: 10.1161/JAHA.123.029880.


A mitochondrial contribution to anti-inflammatory shear stress signaling in vascular endothelial cells.

Coon B, Timalsina S, Astone M, Zhuang Z, Fang J, Han J J Cell Biol. 2022; 221(7).

PMID: 35695893 PMC: 9198948. DOI: 10.1083/jcb.202109144.


Recovery of limb perfusion and function after hindlimb ischemia is impaired by arterial calcification.

Zettervall S, Wang X, Monk S, Lin T, Cai Y, Guzman R Physiol Rep. 2021; 9(16):e15008.

PMID: 34405571 PMC: 8371346. DOI: 10.14814/phy2.15008.


Evaluation of skeletal muscle perfusion in a canine hind limb ischemia model using CT perfusion imaging.

Wang T, Su H, Gu J, Chen Q, Xu Q, Chen B Diagn Interv Radiol. 2019; 26(1):28-33.

PMID: 31650969 PMC: 7075588. DOI: 10.5152/dir.2019.18478.


References
1.
Lederman R, Mendelsohn F, Anderson R, Saucedo J, Tenaglia A, Hermiller J . Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002; 359(9323):2053-8. DOI: 10.1016/s0140-6736(02)08937-7. View

2.
Sasaki K, Duan J, Murohara T, Ikeda H, Shintani S, Shimada T . Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol. 2003; 42(2):364-72. DOI: 10.1016/s0735-1097(03)00629-6. View

3.
Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K . Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 2002; 105(12):1491-6. DOI: 10.1161/01.cir.0000012146.07240.fd. View

4.
Aviles R, Annex B, Lederman R . Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br J Pharmacol. 2003; 140(4):637-46. PMC: 1350957. DOI: 10.1038/sj.bjp.0705493. View

5.
Salven P, Hattori K, Heissig B, Rafii S . Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 2002; 16(11):1471-3. DOI: 10.1096/fj.02-0134fje. View